Drug Discovery

16 Jan 2019
- Drug Discovery
- Research & Development
Bioharmony, Boehringer to advance bacteriophage lysin therapeutics to treat MDR bacterial infections

By PBR Staff Writer

Bioharmony Therapeutics, a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, has entered into a collaborative research and licensing agreement with Boehringer Ingelheim to develop bacteriophage lysins for the treatment of multidrug resistant (MDR) Acinetobacter infections, a frequent cause of hospital-acquired pneumonia and life-threatening blood or wound infections.
14 Jan 2019
Drug Discovery
Research & Development
Ascletis and Alphamab sign licensing deal for anti-PD-L1 to treat hepatitis B and other viral diseases

By PBR Staff Writer

Ascletis Pharma (Ascletis, 1672.HK) and Suzhou Alphamab jointly announce that Ascletis' subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing agreement for anti-PD-L1 KN035 to treat hepatitis B and other viral diseases in Greater China (Ascletis code: ASC22).
14 Jan 2019
Drug Discovery
Research & Development
Charles River, Atomwise collaborate on AI-driven drug discovery

By PBR Staff Writer

Charles River Laboratories International has collaborated with Atomwise on integrated and artificial intelligence (AI)-driven drug discovery.
10 Jan 2019
Drug Discovery
Research & Development
Agenus to use Selexis’ technology to produce therapeutic proteins

By PBR Staff Writer

Selexis has expanded its alliance with clinical-stage immuno-oncology company Agenus by signing additional commercial license agreements (CLAs).
10 Jan 2019
Drug Discovery
Research & Development
Elevian, Insilico collaborate to discover drugs for aging

By PBR Staff Writer

Elevian and Insilico Medicine have announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets.
09 Jan 2019
Drug Discovery
Research & Development
CANbridge, WuXi expand rare disease partnership

By PBR Staff Writer

CANbridge Pharmaceuticals and WuXi Biologics have expanded their rare disease therapeutics partnership to enable the former to discover, develop and commercialize four additional drug candidates.
08 Jan 2019
Drug Discovery
Research & Development
Pfizer to utilize CytoReason’s machine learning model for drug discovery

By PBR Staff Writer

Pfizer has signed a collaboration agreement to use CytoReason’s machine learning model of the immune system for drug discovery.
07 Jan 2019
Drug Discovery
Research & Development
Gilead, Yuhan to co-develop new therapies for NASH in $785m deal

By PBR Staff Writer

Gilead Sciences has signed a licensing and collaboration agreement, potentially worth $785m, with South Korea-based Yuhan to develop new therapeutic candidates for the treatment of advanced fibrosis due to nonalcoholic steatohepatitis (NASH).
07 Jan 2019
Drug Discovery
Research & Development
Adaptive, Genentech to collaborate on personalized cellular therapies for cancer

By PBR Staff Writer

Adaptive Biotechnologies has entered into a worldwide collaboration and license agreement with Roche Group’s Genentech to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a range of cancers.
07 Jan 2019
Drug Discovery
Research & Development
Sanofi to invest €80m in biopharmaceutical firm BioNTech

By PBR Staff Writer

French multinational pharmaceutical company Sanofi investing €80m in equity in BioNTech, which is claimed to be the Europe’s largest privately-held biopharmaceutical firm focused on the development of individualized therapies for cancer and the prevention of infectious diseases.

Drug Discovery

Research & Development

Roche and C4 Therapeutics to advance degrader-antibody conjugates research

Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Drug Discovery

Bioharmony, Boehringer to advance bacteriophage lysin therapeutics to treat MDR bacterial infections

Ascletis and Alphamab sign licensing deal for anti-PD-L1 to treat hepatitis B and other viral diseases

Charles River, Atomwise collaborate on AI-driven drug discovery

Agenus to use Selexis’ technology to produce therapeutic proteins

Elevian, Insilico collaborate to discover drugs for aging

CANbridge, WuXi expand rare disease partnership

Pfizer to utilize CytoReason’s machine learning model for drug discovery

Gilead, Yuhan to co-develop new therapies for NASH in $785m deal

Adaptive, Genentech to collaborate on personalized cellular therapies for cancer

Sanofi to invest €80m in biopharmaceutical firm BioNTech

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found